Sugi Predict

Sugi Predict / Compounds / SCHEMBL18940647

SCHEMBL18940647

SCHEMBL18940647

CNc1c(N)cc(C(=O)OC)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.49
▸ USP2 O75604 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ GAA P10253 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ ATM Q13315 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31215291 0.98 KDM4E (0.47) KDM4EUSP2ALDH1A1GAAMAPT
Hydrochloric Acid SCHEMBL18940563 0.98 KDM4E (0.47) KDM4EUSP2ALDH1A1GAAMAPT
SCHEMBL10682199 0.88 MAPT (0.51) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL18969596 0.87 LMNA (0.53) KDM4EALDH1A1GAALMNAL3MBTL1
SCHEMBL28306097 0.87 CA12 (0.53) KDM4EALDH1A1LMNAL3MBTL1HTT
SCHEMBL29240411 0.87 TSHR (0.49) KDM4EALDH1A1MAPTLMNAL3MBTL1
SCHEMBL30469473 0.87 TSHR (0.49) KDM4EALDH1A1MAPTLMNAL3MBTL1
SCHEMBL31215271 0.83 USP2 (0.43) KDM4EUSP2ALDH1A1GAAMAPT
SCHEMBL18940642 0.83 USP2 (0.43) KDM4EUSP2ALDH1A1GAAMAPT
SCHEMBL8040178 0.83 KDM4E (0.51) KDM4EUSP2ALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF REGOR PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
EP-3885342-B1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2024-11-20 — — EP disclosed
US-11981680-B2 Substituted thienopyrroles as PAD4 inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2024-05-14 — — US disclosed
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 — — US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 — — CN disclosed
US-11878965-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-01-23 — — US disclosed
EP-4267562-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-11-01 — — EP disclosed
CN-112566916-B Substituted Thienopyrroles as PAD4 Inhibitors 百时美施贵宝公司 2023-10-20 — — CN disclosed
WO-2023083365-A1 PAD4 INHIBITORS AND USE THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2023-05-19 — — WO disclosed
US-20230090053-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-03-23 — — US disclosed
US-9963448-B2 Bicyclic inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-9963448-B2 Bicyclic inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
US-9963448-B2 Bicyclic inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-05-08 — — US disclosed
WO-2018022897-A1 COVALENT INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-02-01 — — WO disclosed
WO-2018022897-A1 COVALENT INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-02-01 — — WO disclosed
WO-2017100594-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2017-06-15 — — WO disclosed
WO-2017100594-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2017-06-15 — — WO disclosed
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. 2017-06-15 — — US disclosed
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. 2017-06-15 — — US disclosed
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. 2017-06-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136607-A1 PAD4 INHIBITORS AND USE THEREOF PADI4, PADI6, PADI2 KDM4E 172/4885USP2 1250/4885ALDH1A1 273/4885
US-20230090053-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 KDM4E 936/4885USP2 682/4885ALDH1A1 2537/4885
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 KDM4E 936/4885USP2 682/4885ALDH1A1 2537/4885
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADI4, PADI1, PADI2 KDM4E 125/4885USP2 445/4885ALDH1A1 955/4885
US-11981680-B2 Substituted thienopyrroles as PAD4 inhibitors PADI4, PADI1, PADI6 KDM4E 120/4885USP2 1114/4885ALDH1A1 142/4885
US-11878965-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 KDM4E 936/4885USP2 682/4885ALDH1A1 2537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback